Macarena R Vial1, Kashif A Khan2, Oisin O'Connell3, S Andrew Peng4, Daniel R Gomez5, Joe Y Chang5, David C Rice6, Reza Mehran6, Carlos J Jimenez3, Horiana B Grosu3, David E Ost3, George A Eapen7. 1. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Clínica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile. 2. Department of Respiratory Medicine, Cork University Hospital/University College Cork, Ireland. 3. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: geapen@mdanderson.org.
Abstract
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) being evaluated for stereotactic ablative body radiotherapy (SABR) are typically staged noninvasively with positron emission tomography/computed tomography (PET/CT). Incorporating endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) into the staging workup of these patients has not been evaluated. Our primary objective was to compare the performance of PET/CT with EBUS-TBNA for intrathoracic nodal assessment among SABR-eligible patients. METHODS: This was a retrospective study consisting of two parts. First, we assessed the concordance for nodal metastasis of PET/CT and EBUS-TBNA. Second, we evaluated clinical outcomes among patients who underwent SABR with and without a prior EBUS-TBNA. RESULTS: We identified 246 eligible patients. Compared with PET/CT, EBUS-TBNA led to a stage shift in 48 of 246 patients (19%). Of 174 N0 patients by PET/CT, 6 (3.4%) had nodal metastasis on EBUS-TBNA. Among 72 clinical N1 patients, 36 (50%) were downstaged to N0 after EBUS-TBNA, therefore becoming eligible for SABR. Concordance between PET/CT and EBUS-TBNA for nodal metastasis was 83% (κ = 0.53). Clinical outcomes of patients who underwent SABR with or without a prior EBUS-TBNA did not differ significantly. CONCLUSIONS: Concordance of PET/CT and EBUS-TBNA for nodal disease was only moderate. Incorporating EBUS-TBNA into the staging workup was beneficial in identifying occult nodal metastasis that would otherwise be left untreated with SABR and in expanding the pool of potentially SABR-eligible patients.
BACKGROUND:Patients with non-small cell lung cancer (NSCLC) being evaluated for stereotactic ablative body radiotherapy (SABR) are typically staged noninvasively with positron emission tomography/computed tomography (PET/CT). Incorporating endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) into the staging workup of these patients has not been evaluated. Our primary objective was to compare the performance of PET/CT with EBUS-TBNA for intrathoracic nodal assessment among SABR-eligible patients. METHODS: This was a retrospective study consisting of two parts. First, we assessed the concordance for nodal metastasis of PET/CT and EBUS-TBNA. Second, we evaluated clinical outcomes among patients who underwent SABR with and without a prior EBUS-TBNA. RESULTS: We identified 246 eligible patients. Compared with PET/CT, EBUS-TBNA led to a stage shift in 48 of 246 patients (19%). Of 174 N0 patients by PET/CT, 6 (3.4%) had nodal metastasis on EBUS-TBNA. Among 72 clinical N1 patients, 36 (50%) were downstaged to N0 after EBUS-TBNA, therefore becoming eligible for SABR. Concordance between PET/CT and EBUS-TBNA for nodal metastasis was 83% (κ = 0.53). Clinical outcomes of patients who underwent SABR with or without a prior EBUS-TBNA did not differ significantly. CONCLUSIONS: Concordance of PET/CT and EBUS-TBNA for nodal disease was only moderate. Incorporating EBUS-TBNA into the staging workup was beneficial in identifying occult nodal metastasis that would otherwise be left untreated with SABR and in expanding the pool of potentially SABR-eligible patients.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Philip Ong; Horiana Grosu; George A Eapen; Macarena Rodriguez; Donald Lazarus; David Ost; Carlos A Jimenez; Rodolfo Morice; Venkata Bandi; Luis Tamara; Lorraine Cornwell; Linda Green; Angela Zhu; Roberto F Casal Journal: Ann Am Thorac Soc Date: 2015-03
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: George A Eapen; Archan M Shah; Xiudong Lei; Carlos A Jimenez; Rodolfo C Morice; Lonny Yarmus; Joshua Filner; Cynthia Ray; Gaetane Michaud; Sara R Greenhill; Mona Sarkiss; Roberto Casal; David Rice; David E Ost Journal: Chest Date: 2013-04 Impact factor: 9.410
Authors: Jonathan M Robson; Sriram Vaidyanathan; Leanne Cheyne; Michael Snee; Kevin Franks; Matthew E J Callister Journal: Clin Lung Cancer Date: 2014-08-15 Impact factor: 4.785
Authors: William R Kennedy; Pamela P Samson; Prashant Gabani; John Nikitas; Jeffrey D Bradley; Michael C Roach; Clifford G Robinson Journal: Radiother Oncol Date: 2020-07-03 Impact factor: 6.280
Authors: Adam R Belanger; Johnathan Hollyfield; Gabriella Yacovone; Agathe S Ceppe; Jason A Akulian; A Cole Burks; M Patricia Rivera; Leslie G Dodd; Jason M Long; Benjamin E Haithcock; Chad V Pecot Journal: J Thorac Dis Date: 2019-08 Impact factor: 2.895
Authors: Aidan Joseph Cole; Nicholas Hardcastle; Guy-Anne Turgeon; Roshini Thomas; Louis B Irving; Barton R Jennings; David Ball; Tomas Kron; Daniel P Steinfort; Shankar Siva Journal: ERJ Open Res Date: 2019-07-15
Authors: Gabriela Martinez-Zayas; Francisco A Almeida; Michael J Simoff; Lonny Yarmus; Sofia Molina; Benjamin Young; David Feller-Kopman; Ala-Eddin S Sagar; Thomas Gildea; Labib G Debiane; Horiana B Grosu; Roberto F Casal; Muhammad H Arain; George A Eapen; Carlos A Jimenez; Laila Z Noor; Shiva Baghaie; Juhee Song; Liang Li; David E Ost Journal: Am J Respir Crit Care Med Date: 2020-01-15 Impact factor: 21.405
Authors: Daniel P Steinfort; Shankar Siva; Kanishka Rangamuwa; Percy Lee; David Fielding; Phan Nguyen; Barton R Jennings; Shaun Yo; Nick Hardcastle; Gargi Kothari; Laurence Crombag; Jouke Annema; Kazuhiro Yasufuku; David E Ost; Louis B Irving Journal: BMC Pulm Med Date: 2022-09-24 Impact factor: 3.320